Introduction
============

Sunitinib is an orally administered multikinase inhibitor that targets several tyrosine kinase inhibitors implicated in tumor growth, pathologic angiogenesis, and metastatic progression ([@r1], [@r2]). According to registration studies, common side effects reported in at least 20% of patients include hypertension, fatigue, gastrointestinal disorders (decreased appetite, diarrhea, stomatitis, nausea, dyspepsia, esophagitis), skin disorders, hematologic disorders (anemia, thrombocytopenia, granulocytopenia), hypothyroidism, etc. Uncommon side effects (\>1:1000-\<1:100 cases) include pancytopenia, tumor lysis syndrome, cardiac disorders, thromboembolic incidents, intestinal perforation, pancreatitis, Stevens-Johnson syndrome, acute renal failure and proteinuria ([@r3]-[@r5]). We report a case of few uncommon sunitinib therapy side effects in a patient with metastatic renal cell carcinoma (mRCC).

Case Report
===========

A 63-year-old woman with medical history of well regulated hypertension, adult renal polycystosis and chronic renal failure stage 3A (glomerular filtration rate (GFR) 47.7 mL/min) was admitted to the hospital due to abdominal pain and nausea, vomiting and elevated blood pressure (up to 180/130 mm Hg), which had started gradually one week before. The patient noticed that symptoms started three weeks after sunitinib therapy for mRCC had been initiated. In June 2010, the patient underwent radical right sided nephrectomy due to renal adenocarcinoma. In March 2012, lung metastases were verified by positron emission tomography-computed tomography. In May 2012, first line treatment for mRCC with sunitinib was initiated. During the first cycle of 50 mg sunitinib daily, the symptoms started after three weeks, so she stopped taking the drug. On hospital admission, laboratory tests revealed elevated serum and urine amylase (138 and 1997 U/L), C-reactive protein (CRP, 90 mg/L), urea (13.4 mmol/L) and creatinine (213 µmol/L; GFR 28.2 mL/min), and lowered platelet (39x10^9^/L) and leukocyte (2.56x10^9^/L) counts and hemoglobin value (100 g/L). Urine test showed proteinuria, erythrocyturia, leukocyturia and granulated cylinder. Abdominal ultrasound revealed bilateral pleural effusions, free fluid in lower abdomen, enlarged left kidney with canal system dilatation and gallbladder concrement of 3 cm in size without bile duct dilatation but the pancreas was not visualized due to meteorism. The patient was diagnosed with acute pancreatitis grade III, acute renal failure grade II (worsening of chronic kidney failure), pancytopenia and urinary infection (graduation according to Common Terminology Criteria for Adverse Events v. 4.03). She was treated symptomatically and, because of persistently elevated CRP and pathologic urine sediment, with antibiotic therapy (amoxicillin/clavulanic acid), which led to subjective and clinical improvement (decrease of serum and urine amylase and CRP, initial decrease of creatinine value). Antihypertensive therapy was also modified. The patient was discharged after five days and further checkups were provided by oncologist in outpatient care. After recovery, in October 2012, the patient started therapy with sorafenib, which she tolerated well.

Discussion
==========

Acute pancreatitis, acute renal failure and pancytopenia, which were all found in our patient, are uncommon side effects of sunitinib therapy. In a phase III study conducted in 2007, Motzer *et al*. compared the efficacy of sunitinib (375 patients) *versus* interferon alfa (360 patients) for mRCC; increase in amylase and lipase level was recorded in 84 (22.4%) patients in sunitinib arm (20.2% of which were grade III and 4.8% grade IV); there were no cases of acute pancreatitis in that study ([@r3]). To the best of our knowledge, only three cases of acute pancreatitis have been reported in the literature, i.e. one patient on combined tyrosine kinase therapy treated for non-small-cell lung carcinoma, one patient on combined therapy with sunitinib, gemcitabine and cisplatin treated for high-grade urothelial carcinoma, and one patient on combined radioimmunotherapy for hepatocellular carcinoma; none has been reported in patients receiving sunitinib for mRCC ([@r6]-[@r8]). Considering renal toxicity, according to the study by Motzer *et al*., increased creatinine values were recorded in 66 (17.6%, of which only one grade III case) patients receiving sunitinib for mRCC ([@r3]). There are few retrospective studies conducted in patients with renal impairment at the start of sunitinib therapy, suggesting that sunitinib is safe in that population (metabolized primarily in the liver) but often causes creatinine level increase and demands dose adjustment due to the higher incidence of non-renal toxicity and hypertension ([@r9]-[@r12]). There are few case reports on acute renal failure in patients receiving sunitinib ([@r13], [@r14]). Although our patient had a history of chronic renal insufficiency, during sunitinib therapy she experienced worsening of her usually stable disease (acute-on-chronic renal failure) and we could not determine with certainty if worsening of her renal function was a consequence of dehydration due to vomiting or an effect of sunitinib. According to registration studies, anemia, leukocytopenia and thrombocytopenia are common adverse events associated with sunitinib therapy; however, to the best of our knowledge, pancytopenia has not yet been reported in postmarketing experience ([@r3], [@r15]).

Conclusion
==========

Acute pancreatitis, renal insufficiency and pancytopenia are rarely described side effects of sunitinib therapy and clear connection between these conditions and drug activity has not yet been determined. Medical specialists who prescribe and treat patients with sunitinib should be aware of the possible occurrence of these conditions and perform regular checkups of treated patients.
